Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Published on 28 September 2026
Dr Chul Kim speaks to ecancer about the final overall survival results from the phase III PAPILLON study.
The results show that first-line amivantamab plus carboplatin-pemetrexed provides a sustained survival benefit in patients with EGFR exon 20 insertion advanced NSCLC.
After a median follow-up of 48.6 months, median overall survival was 34.3 months with amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone, despite 76% of patients in the chemotherapy arm subsequently receiving amivantamab.
Dr Kim also covers the impact of treatment crossover, the prespecified adjusted survival analysis, safety and patient reported outcomes.
This information is intended for health care professionals only. The information is not intended for US health care professionals.